Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an update.
NIOX Group plc has corrected an earlier announcement regarding a block listing application, clarifying that an adviser was incorrectly included in the original notice. The company has applied for a block admission of 165,413 new ordinary shares of 0.08 pence each to be admitted to trading on AIM, with these shares to be issued as required under its 2023 Save As You Earn employee share plan and expected to be admitted on 21 January 2026, ranking equally with existing shares and modestly expanding its share capital base.
The most recent analyst rating on (GB:NIOX) stock is a Hold with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven by its strong financial performance and positive corporate events, which are offset by neutral technical indicators and a high P/E ratio suggesting overvaluation. The company’s robust cash flow and low leverage provide a stable foundation, while recent corporate actions signal confidence in future growth.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
NIOX Group plc is a UK-listed medical diagnostics company whose shares trade on AIM, focusing on products and technologies used in respiratory and related healthcare settings. Its capital structure includes ordinary shares of 0.08 pence each, which are traded on the London Stock Exchange’s junior market.
Average Trading Volume: 950,664
Technical Sentiment Signal: Buy
Current Market Cap: £286.7M
Learn more about NIOX stock on TipRanks’ Stock Analysis page.